LGVN
USDLongeveron Inc. Class A Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$0.820
Haut
$0.820
Bas
$0.800
Volume
0.38M
Fondamentaux de l'Entreprise
Capitalisation Boursière
16.8M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.95M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II)
Actions Connexes
RNGR
Ranger Energy Services Inc.
OSK
Oshkosh Corporation (Holding Company)Common Stock
KTTA
Pasithea Therapeutics Corp.
SOHOO
Sotherly Hotels Inc. 7.875% Series C Cumulative Redeemable Perpetual Preferred Stock
LGND
Ligand Pharmaceuticals Incorporated
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.